PROFILPELAJAR.COM

TMU4142

TMU4142
Clinical data
Other namesTMU-4142
Drug classSerotonin 5-HT1A receptor biased agonist
ATC code
  • None
Chemical and physical data
FormulaC23H30N3O4
Molar mass412.510 g·mol−1
3D model (JSmol)
  • O[C](CNCCCN1C(=O)CC2(CCCC2)CC1=O)COc3cccc4[nH]ccc34
  • InChI=1S/C23H30N3O4/c27-17(16-30-20-6-3-5-19-18(20)7-11-25-19)15-24-10-4-12-26-21(28)13-23(14-22(26)29)8-1-2-9-23/h3,5-7,11,24-25,27H,1-2,4,8-10,12-16H2
  • Key:NJZRIWWCDITGNS-UHFFFAOYSA-N

TMU4142 is a potent and selective serotonin 5-HT1A receptor biased agonist.[1] It is a preferential near-full agonist of the GoA pathway with weak agonism of the Gi3 pathway and little or no β-arrestin2 recruitment.[1]

Presynaptic serotonin 5-HT1A autoreceptors predominantly signal via the Gi3 pathway in the dorsal raphe nucleus (DRN) and are associated with feedback inhibition that may hamper therapeutic effects, whereas postsynaptic serotonin 5-HT1A heteroreceptors couple mainly to Go pathways in hippocampal and cortical areas and are thought to mediate antidepressant-like effects.[1] As such, TMU4142 is a selective postsynaptic serotonin 5-HT1A receptor agonist with the potential for greater antidepressant activity than other serotonin 5-HT1A receptor agonists, such as 8-OH-DPAT, buspirone, gepirone, F-15599 (NLX-101), and vilazodone, among others.[1] On the other hand, the Gz pathway is thought to be involved in anxiolytic-like effects.[1] Analogously to TMU4142, pindolol is a moderate-efficacy partial agonist of the Go pathways but a very weak partial agonist or antagonist of Gi pathways.[1]

TMU4142 produces rapid antidepressant-like effects in rodents without modifying serotonin levels or neuronal firing rates in the DRN.[1] This is in contrast to other serotonin 5-HT1A receptor agonists like buspirone and F-13714, which are strong presynaptic serotonin 5-HT1A receptor agonists and reduce DRN serotonin levels and neuronal firing rates.[1] It is also in contrast to serotonin reuptake inhibitors like fluoxetine, which work by elevating serotonin levels, in turn activating both pre- and post-synaptic serotonin 5-HT1A receptors, and which did not show rapid antidepressant-like effects in rodents.[1]

TMU4142 was first described in the scientific literature by Chunyu Wang and colleagues in 2025.[1] It is a combined derivative or analogue of pindolol and azapirones like buspirone with improved pharmacological properties such as selectivity, biased agonism, and activational efficacy.[1]

See also

References

  1. ^ a b c d e f g h i j k Wang C, Zhang N, Shao Y, Li T, Zhang M, Gao M, et al. (November 2025). "Pathway-selective 5-HT1AR agonist as a rapid antidepressant strategy". Cell. doi:10.1016/j.cell.2025.10.022. PMID 41232528.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.